切换至 "中华医学电子期刊资源库"

中华结直肠疾病电子杂志 ›› 2016, Vol. 05 ›› Issue (06) : 480 -483. doi: 10.3877/cma.j.issn.2095-3224.2016.06.005

所属专题: 文献

论著

重组人生长激素治疗溃疡性结肠炎临床对照研究
万晶晶1, 徐东升2, 杨丙寅2, 马兴刚2,()   
  1. 1. 210023 南京中医药大学研究生院;223002 淮安,徐州医学院附属淮安医院(江苏淮安市第二人民医院)消化科
    2. 223002 淮安,徐州医学院附属淮安医院(江苏淮安市第二人民医院)消化科
  • 收稿日期:2016-09-13 出版日期:2016-12-25
  • 通信作者: 马兴刚
  • 基金资助:
    淮安市科技局科技计划资助项目(No.HAS2013022)

Clinical control study of recombinant human growth hormone in the treatment of ulcerative colitis

Jingjing Wan1, Dongsheng Xu2, Bingyin Yang2, Xinggang Ma2,()   

  1. 1. Graduated School of Nanjing University of Chinese Medicine, Nanjing 210023, China; Department of Gastroenterology, Hospital of Huai′an Affiliated to Xuzhou Medical College (Second People′s Hospital of Huai′an) , Huai′an 223002, China
    2. Department of Gastroenterology, Hospital of Huai′an Affiliated to Xuzhou Medical College (Second People′s Hospital of Huai′an) , Huai′an 223002, China
  • Received:2016-09-13 Published:2016-12-25
  • Corresponding author: Xinggang Ma
  • About author:
    Corresponding author: Ma Xinggang, Email:
引用本文:

万晶晶, 徐东升, 杨丙寅, 马兴刚. 重组人生长激素治疗溃疡性结肠炎临床对照研究[J/OL]. 中华结直肠疾病电子杂志, 2016, 05(06): 480-483.

Jingjing Wan, Dongsheng Xu, Bingyin Yang, Xinggang Ma. Clinical control study of recombinant human growth hormone in the treatment of ulcerative colitis[J/OL]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2016, 05(06): 480-483.

目的

研究重组人生长激素(r-hGH)在溃疡性结肠炎(ulcerative colitis,UC)治疗中的作用。

方法

选取2011至2016年徐州医学院附属淮安医院溃疡性结肠炎患者55例,随机分组为研究组(30例)、对照组(25例),两组患者在年龄、职业、病程、肠镜下病变范围均有可比性,Mayo评分差异无统计学意义(t值=0.163,P=0.871)。两组患者均进行基础治疗共14 d,研究者则加用重组人生长激素4 iu每天一次皮下注射,共14 d,两组患者治疗前后分别作Mayo评分及检查血清肿瘤坏死因子-α(TNF-α)、白细胞介素-1β(IL-1β)。

结果

研究组治疗前后Mayo评分改善(t值=15.425,P<0.001)、TNF–α下降(t值=7.080,P<0.001)差异均有显著性统计学意义,而IL-1β变化差异无显著性统计学意义(t值=0.402,P=0.691)。对照组治疗前后Mayo评分改善差异有显著性统计学意义(t值=9.165,P<0.001),TNF-α(t值=1.472,P=0.154)、IL-1β(t值=0.941,P=0.356)比较差异无显著性统计学意义。

结论

重组人生长激素可以有效降低溃疡性结肠炎患者血清TNF-α水平,促进溃疡性结肠炎患者大肠粘膜的修复。

Objective

To study the effect of recombinant human growth hormone (r-hGH) in the treatment of ulcerative colitis.

Methods

Fifty-five patients with ulcerative colitis were collected from 2011 to 2016 in Second People′s Hospital of Huai′an, and were randomly grouped into research group (30 cases) and control group (25 cases). Two groups of patients are comparable with age, occupation, duration, colonoscopy lesions scope and Mayo score (t=0.163, P=0.163). Two groups of patients were under a total of 14 days treatment. The research group was added with subcutaneous injection of recombinant human growth hormone, 4 iu qd, 14 days. Two groups of patients were analyzed the Mayo score and serum tumor necrosis factor alpha (TNF alpha), interleukin 1 beta (IL-1 beta) before and after treatment respectively.

Results

In research group, the Mayo score (t=15.425, P<0.001) and TNF alpha (t=7.080, P<0.001) were of highly significant statistical difference before and after treatment, there was no significant statistical difference in IL-1 beta changes (t=0.402, P=0.402). In the control group, the Mayo score was of significant statistical difference (t=9.165, P=9.165) before and after treatment, the TNF alpha beta (t=1.472, P=0.154), IL-1 (t=0.941, P=0.356) was of no significant statistical difference.

Conclusion

The recombinant human growth hormone can effectively reduce the blood level of TNF alpha in ulcerative colitis patients, promoting restoration of large intestine mucosa in patients with ulcerative colitis.

表1 两组患者治疗前后Mayo评分分析(±s,分)
表2 两组患者治疗前后血清TNF-α比较(±s,pg/ml)
表3 两组患者治疗前后血清IL-1β比较(±s,pg/ml)
[1]
何小华. 炎症性肠病发病的相关免疫机制[J]. 南昌大学学报(医学版), 2011, 51(10): 93-96.
[2]
Pichai MV,Ferguson LR. Potential prospects of nanomedicine for targeted therapeutics in inflammatory bowel diseases[J]. World J Gastroenterol, 2012, 18(23): 2895-2901.
[3]
江学良. 溃疡性结肠炎现代治疗诊疗手册[M]. 北京: 中国医药科技出版社, 2006: 81-90.
[4]
Ding HG,Shan J,Zhang B, et al. Combined human growth hormone and lactulose for prevention and treatment of multiple organ dysfunction in patients with severe chronic hepatitis B[J]. World J Gastroenterol, 2005, 11(19): 2981-2983.
[5]
郭光华,蔡晨,李国辉, 等. 肠内免疫营养联合重组人生长激素对烫伤大鼠的治疗作用[J]. 中国危重病急救医学, 2006, 18(1): 42-45.
[6]
王兴鹏,王冰娴,吴建新, 等. 生长激素对实验性急性坏死性胰腺炎肠道细菌移居的影响[J]. 中华消化杂志, 2000, 20(3): 171-174.
[7]
Scopa CD,Koureleas S,Tsamandas AC, et al. Beneficial effects of growth hormone and insulin-like growth factor 1 on intestinal bacterial translocation, endotoxemia, and apoptosis in experimentally jaundiced rats[J]. J Am Coll Surg, 2000, 190(4): 423-431.
[8]
Yang ZW,Li JG,Mao XG, et al. Effects of recombinant human growth hormone on intestinal translocation of bacteria and endotoxin in rats with obstructive jaundice[J]. Hepatobiliary Pancreat Dis Int, 2005, 4(3): 445-449.
[9]
黄英,王树人,应明英, 等. 重组人生长激素对败血症大鼠的实验治疗[J]. 中国病理生理杂志, 2003, 19(9): 1253-1256.
[10]
Han X,Sosnowska D,Bonkowski EL, et al. Growth Hormone Inhibits Signal Transducer and Activator of Transcription 3 Activation and Reduces Disease Activity in Murine Colitis[J]. Gastroenterology, 2005, 129(1): 185-203.
[11]
Kara E,Sungurtekin H,Sungurtekin U, et al. The effect of recombinant human growth hormone (rhGH) on trinitrobenzene sulfonic acid-induced colitis in rats. An experimental study[J]. Inflamm Bowel Dis, 2004, 10(2): 112-115.
[12]
Coburn L A,Gong X,Singh K, et al. L-arginine supplementation improves responses to injury and inflammation in dextran sulfate sodium colitis[J]. Plos One, 2012, 7(3): e33546.
[13]
秦爽,贺育兰,杨静, 等. 重组人生长激素对内毒素诱导人巨噬细胞产生TNF-α、IL-1β含量的影响[J]. 中国感染控制杂志, 2008, 7(1): 9-11.
[14]
Goh KL,Xiao SD. Inflammatory bowel disease: A survey of the epidemiology in Asia[J]. J Dig Dis, 2009, 10(1): 1-6.
[15]
尹岸民. 溃疡性结肠炎患者血浆炎性反应细胞因子水平的变化[J]. 吉林医学, 2011, 32(27): 5682-5682.
[16]
Owczarek D,Cibor D,Głowacki MK, et al. TNF-α and soluble forms of TNF receptors 1 and 2 in the serum of patients with Crohn′s disease and ulcerative colitis[J]. Pol Arch Med Wewn, 2012, 122(12): 616-623.
[17]
Coccia M,Harrison OJ,Schiering C, et al. IL-1β mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4Th17 cells[J]. J Exp Med, 2012, 209(9): 1595-1609.
[18]
朱向东,曹燕飞,王燕, 等. 溃疡性结肠炎大鼠血清白细胞介素-1β、肿瘤坏死因子-α、白细胞介素-4动态表达规律[J]. 中国老年学杂志, 2015, 35(2): 410-412.
[19]
唐月华,王小平. 溃疡性结肠炎患者血清IL-1β和IL-18的表达及临床意义[J]. 河北医药, 2015, 37(10): 1534-1535.
[1] 史学兵, 谢迎东, 谢霓, 徐超丽, 杨斌, 孙帼. 声辐射力弹性成像对不可切除肝细胞癌门静脉癌栓患者放射治疗效果的评价[J/OL]. 中华医学超声杂志(电子版), 2024, 21(08): 778-784.
[2] 曹琮沅, 黄烁金, 何倩婷, 王安训. 平阳霉素复合剂治疗口腔颌面部脉管畸形的有效性和安全性[J/OL]. 中华口腔医学研究杂志(电子版), 2024, 18(06): 368-374.
[3] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[4] 杨建波, 马欢, 黄小梅, 刘华柱. 结肠镜辅助下EMR、CSP和RFA术治疗直径<1cm结直肠息肉的疗效和安全性比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 76-79.
[5] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[6] 张朝军, 袁新普. 腹腔镜辅助低位直肠癌根治术[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 602-602.
[7] 许月芳, 刘旺, 曾妙甜, 郭宇姝. 多粘菌素B和多粘菌素E治疗外科多重耐药菌感染临床疗效及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 700-703.
[8] 刘柏隆, 周祥福. 压力性尿失禁阶梯治疗的项目介绍[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 125-125.
[9] 刘柏隆. 女性压力性尿失禁阶梯治疗之手术治疗方案选择[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 126-126.
[10] 石海波, 赵旭东, 王聪, 曲巍. 气肿性肾盂肾炎、气肿性膀胱炎并脓毒性休克一例报道并文献复习[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 644-647.
[11] 中华医学会器官移植学分会. 肝移植术后缺血性胆道病变诊断与治疗中国实践指南[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 739-748.
[12] 陈伟杰, 何小东. 胆囊癌免疫靶向治疗进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 763-768.
[13] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
[14] 刘福成, 赵欣, 乔海朋, 刘晓峰, 张翀, 张宗明. 保留左结肠动脉的肠系膜下动脉根部淋巴结清扫对腹腔镜直肠癌根治术的疗效影响[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 647-653.
[15] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
阅读次数
全文


摘要